<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000393543"><TermName>rebeccamycin analog</TermName><TermPronunciation>(reh-BEH-kuh-MY-sin A-nuh-log)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called antitumor antibiotics and topoisomerase inhibitors. Also called NSC 655649.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713403" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;rebeccamycin analog&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713402" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;análogo de la rebecamicina&quot;" language="es" id="_4"/><SpanishTermName>análogo de la rebecamicina</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Es un tipo de antibiótico antitumoral y de inhibidor de la topoisomerasa. También se llama NSC 655649.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-11-22</DateFirstPublished><DateLastModified>2006-11-07</DateLastModified></GlossaryTerm>
